Publications

  • 1. M. Schneider, J.-L. Pons, G. Labesse, W. Bourguet, In Silico Predictions of Endocrine Disruptors Properties., Endocrinology 160, 2709–2716 (2019).
  • 2. M. J. den Broeder, J. Ballangby, L. M. Kamminga, P. Aleström, J. Legler, L. C. Lindeman, J. H. Kamstra, Inhibition of methyltransferase activity of enhancer of zeste 2 leads to enhanced lipid accumulation and altered chromatin status in zebrafish., Epigenetics Chromatin 13, 5 (2020).
  • 3. J. Legler, D. Zalko, F. Jourdan, M. Jacobs, B. Fromenty, P. Balaguer, W. Bourguet, V. Munic Kos, A. Nadal, C. Beausoleil, S. Cristobal, S. Remy, S. Ermler, L. Margiotta-Casaluci, J. L. Griffin, B. Blumberg, C. Chesné, S. Hoffmann, P. L. Andersson, J. H. Kamstra, The GOLIATH Project: Towards an Internationally Harmonised Approach for Testing Metabolism Disrupting Compounds, Int. J. Mol. Sci. 21, 3480 (2020).
  • 4. X. M. Ren, Y. Kuo, B. Blumberg, Agrochemicals and obesity, Mol. Cell. Endocrinol. 515, 110926 (2020).5. M. Schneider, J. L. Pons, W. Bourguet, G. Labesse, A. Elofsson, Towards accurate high-throughput ligand affinity prediction by exploiting structural ensembles, docking metrics and ligand similarity, Bioinformatics 36, 160–168 (2020).
  • 6. J. Allard, S. Bucher, J. Massart, P. Ferron, D. Le Guillou, R. Loyant, Y. Daniel, Y. Launay, N. Buron, K. Begriche, A. Borgne-sanchez, B. Fromenty, Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells : proof of multiple mechanism-based toxicity, Cell. Biol. Toxicol. (2020).